Emergent BioSolutions Receives $20 Million Contract to Supply Anthrax Vaccine to US Military

MT Newswires Live01-09 00:27

Emergent BioSolutions (EBS) said Wednesday that the US Department of Defense has exercised a contract option to buy around $20 million of the company's BioThrax anthrax vaccine.

In December, the company shipped about $7 million of the pre-exposure vaccine to the Pentagon for distribution among all six branches of the US military, with the remaining deliveries expected over the rest of 2025, it said.

The purchase was authorized through the company's existing procurement contract with the Defense Department and its Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense.

Emergent last month also disclosed a $50 million contract option to supply up to $50 million of its Cyfendus anthrax vaccine to the federal government expected to be completed by April.

Price: 9.99, Change: -0.29, Percent Change: -2.80

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2502882777?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-09 00:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2502882777","market":"fut","top_or_hot":-1,"title":"Emergent BioSolutions Receives $20 Million Contract to Supply Anthrax Vaccine to US Military","media":"MT Newswires Live","content":"<html><body><p> Emergent BioSolutions (EBS) said Wednesday that the US Department of Defense has exercised a contract option to buy around $20 million of the company's BioThrax anthrax vaccine.</p><p>In December, the company shipped about $7 million of the pre-exposure vaccine to the Pentagon for distribution among all six branches of the US military, with the remaining deliveries expected over the rest of 2025, it said.</p><p>The purchase was authorized through the company's existing procurement contract with the Defense Department and its Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense.</p><p>Emergent last month also disclosed a $50 million contract option to supply up to $50 million of its Cyfendus anthrax vaccine to the federal government expected to be completed by April.</p><p>Price: 9.99, Change: -0.29, Percent Change: -2.80</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Emergent BioSolutions Receives $20 Million Contract to Supply Anthrax Vaccine to US Military</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEmergent BioSolutions Receives $20 Million Contract to Supply Anthrax Vaccine to US Military\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-09 00:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Emergent BioSolutions (EBS) said Wednesday that the US Department of Defense has exercised a contract option to buy around $20 million of the company's BioThrax anthrax vaccine.In December, the ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2502882777","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2502882777","pubTimestamp":1736353635,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Emergent BioSolutions  said Wednesday that the US Department of Defense has exercised a contract option to buy around $20 million of the company's BioThrax anthrax vaccine.In December, the company shipped about $7 million of the pre-exposure vaccine to the Pentagon for distribution among all six branches of the US military, with the remaining deliveries expected over the rest of 2025, it said.The purchase was authorized through the company's existing procurement contract with the Defense Department and its Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense.Emergent last month also disclosed a $50 million contract option to supply up to $50 million of its Cyfendus anthrax vaccine to the federal government expected to be completed by April.Price: 9.99, Change: -0.29, Percent Change: -2.80","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4583":"猴痘概念","EBS":"Emergent Biosolutions"},"translate_title":"Emergent BioSolutions获得2000万美元合同向美军供应炭疽疫苗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EBS":1},"content_text":"Emergent BioSolutions (EBS) said Wednesday that the US Department of Defense has exercised a contract option to buy around $20 million of the company's BioThrax anthrax vaccine.In December, the company shipped about $7 million of the pre-exposure vaccine to the Pentagon for distribution among all six branches of the US military, with the remaining deliveries expected over the rest of 2025, it said.The purchase was authorized through the company's existing procurement contract with the Defense Department and its Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense.Emergent last month also disclosed a $50 million contract option to supply up to $50 million of its Cyfendus anthrax vaccine to the federal government expected to be completed by April.Price: 9.99, Change: -0.29, Percent Change: -2.80","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,merge","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2502882777"}